Printer Friendly

IDEC PHARMACEUTICALS STARTING TO UNIFY FACILITIES AND STAFF IN SAN DIEGO

 LA JOLLA and MOUNTAIN VIEW, Calif., Feb. 22 /PRNewswire/ -- IDEC Pharmaceuticals Corporation (NASDAQ: IDPH) today announced that the unification of the company's staff in San Diego has begun. The company's medical affairs, clinical trials and regulatory groups will move to temporary quarters in San Diego on March 1. The company expects that all employees relocating from Mountain View, as well as employees currently in the company's La Jolla facility, will move to its new facility by the end of June.
 As previously announced, IDEC Pharmaceuticals has leased a 70,000-square-foot building in San Diego as the site for its new corporate headquarters, research laboratories and mammalian cell- culture pilot plant. All employees at the company's Mountain View location were encouraged to relocate to San Diego and were offered financial assistance to make the move.
 "We are very pleased that two-thirds of our Mountain View staff have chosen to move with us," said William H. Rastetter, Ph.D., president and chief executive officer. "Other employees who have not elected to relocate are continuing to work at IDEC during the transition period, so that we can bring together our Mountain View and La Jolla operations with a minimal amount of disruption. We would like to express our appreciation to our entire Mountain View staff for their dedication and commitment to IDEC since our unification plans were announced a year ago."
 "Among those who have elected to remain in the Bay Area -- and will therefore be leaving IDEC -- is Clifford Orent, senior vice president and chief operating officer," Dr. Rastetter said. "Cliff will be employed fulltime at the company until the end of February and will then continue working with IDEC as a consultant on selected projects. As is true for others in Mountain View, his decision is a personal one. We are grateful for his thoughtful and valued leadership over the past four years, and we wish him and other colleagues remaining in the Bay Area every success in their chosen career paths."
 "We are very excited about our unification," Dr. Rastetter added. "Scientists who have been separated between two sites will finally be able to reap the rewards of regular interaction and the cross- fertilization of ideas. Individuals looking for greater flexibility in their career paths are likely to have a broader range of growth opportunities, including not only moves within their department but also moves between departments. Everyone will be able to operate more efficiently, productively and cost-effectively. Equally important, IDEC's stockholders are expected to benefit from anticipated improvements in the company's ability to identify new product opportunities and accelerate the development process."
 IDEC Pharmaceuticals is focused on the development of antibody- based therapies for the treatment of a wide range of human diseases. These agents typically are designed to act through immune system mechanisms and potentially offer greater specificity of action, longer therapeutic effect and lower toxicity than is typical of existing therapies. Moreover, the company's product candidates potentially can be administered in outpatient settings, helping to reduce overall treatment costs. Several human clinical studies are in progress using product candidates for the treatment of B-cell lymphomas, malignant melanoma and HIV infection. Late-stage preclinical testing of an anti-CD4 antibody is under way for the treatment of autoimmune diseases, as part of the company's product- development collaboration with SmithKline Beecham. Separate from this collaboration, IDEC Pharmaceuticals is developing additional primatized antibodies for a variety of therapeutic applications.
 IDEC Pharmaceuticals is headquartered at 11099 North Torrey Pines Road, La Jolla, CA 92037. Company operations also are located in Mountain View, CA.
 /EDITOR'S NOTE: IDEC Pharmaceuticals has issued two additional press releases today entitled: "IDEC Pharmaceuticals and SmithKline Beecham Expand Primatized' Antibody Collaboration to Include Asia" and "IDEC Pharmaceuticals Significantly Expands Lymphoma Clinical Program."/
 -0- 2/22/93
 /CONTACT: Richard W. Krawiec, director, investor relations and corporate communications, 619-458-0600, or Clifford Orent, senior VP and COO, 415-940-1200, both of IDEC Pharmaceuticals/
 (IDPH)


CO: IDEC Pharmaceuticals Corp. ST: California IN: MTC SU: PER

LS-JB -- SD005 -- 8824 02/22/93 09:10 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 22, 1993
Words:669
Previous Article:SUN COMPANY UPDATES ANALYSTS ON COMPANY'S RESTRUCTURING PLAN
Next Article:MICRONICS CELEBRATES SHIPMENT OF 1,000,000 SYSTEM BOARDS; 1992 SHIPMENTS REPRESENT U.S. MARKET SHARE OF ALMOST 16 PERCENT FOR 486-BASED SYSTEMS
Topics:


Related Articles
IDEC PHARMACEUTICALS EXPANDING TO NEW HEADQUARTERS; UNIFYING ALL COMPANY OPERATIONS IN ONE LOCATION
IDEC PHARMACEUTICALS AND SMITHKLINE BEECHAM EXPAND 'PRIMATIZED' ANTIBODY COLLABORATION TO INCLUDE ASIA
IDEC PHARMACEUTICALS SIGNIFICANTLY EXPANDS LYMPHOMA CLINICAL PROGRAM
IDEC PHARMACEUTICALS REPORTS THIRD QUARTER 1993 RESULTS
GENENTECH LICENSES IDEC PHARMACEUTICALS' TECHNOLOGY FOR HIGH-LEVEL GENE EXPRESSION
Alexandria Real Estate Equities Breaking Ground on Second Office/Laboratory Development Project in San Diego.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters